Cipla top loser in Nifty as US FDA issues warning letter
New Delhi: Cipla shares were down by more than 7 per cent Thursday after the US FDA issued a warning ...
Read moreNew Delhi: Cipla shares were down by more than 7 per cent Thursday after the US FDA issued a warning ...
Read moreNew Delhi: The Indian equity indices -- S&P BSE Sensex and NSE Nifty50 -- settled higher Friday, the last trading ...
Read moreNew Delhi: India’s drug regulator Drugs Controller General of India (DCGI) has granted permission to Cipla to import Moderna's Covid-19 ...
Read moreNew Delhi: Cipla Limited announced the commercialisation of a polymerase chain reaction (RT-PCR) test kit ‘ViraGen for Covid-19 in India, ...
Read moreNew Delhi: Pharma major Cipla said Wednesday it has launched its generic version of anti-viral drug remdesivir at a price ...
Read moreNew Delhi: Four domestic pharma firms – Cipla, Jubilant Life Sciences, Hetero and Mylan – have entered into non-exclusive licensing agreements ...
Read more